BioSpace News Archive

Exelixis, Inc. and Ipsen announced that COSMIC-312, the ongoing phase 3 pivotal trial evaluating cabozantinib in combination with atezolizumab versus sorafenib in patients with previously untreated advanced hepatocellular carcinoma, met one of the primary endpoints, demonstrating significant improvement in progression-free survival at the planned primary analysis.

Targovax ASA, announces that Victor Levitsky, Chief Scientific Officer of Targovax, is invited to present at the 4th Annual Next Gen Immuno-Oncology Virtual Congress-US Edition.

Orphazyme A/S, a late-stage biopharmaceutical company, announced 24-month interim results of an open-label extension trial, providing efficacy and safety data for its investigational treatment arimoclomol in Niemann-Pick disease type C for up to 36 months.

Waters Corporation announced an expansion of its joint work with the Bioprocessing Technology Institute, a research institute of Singapore’s Agency for Science, Technology and Research.

Chugai Pharmaceutical Co., Ltd. announced that Roche has been granted Marketing Authorization from the European Commission for the pH-dependent binding humanized anti-IL-6 receptor monoclonal antibody Enspryng®, created by Chugai, as the first subcutaneous treatment option for adults and adolescents from 12 years of age living with anti-aquaporin-4 antibody seropositive neuromyelitis optica spectrum disorder, as a monotherapy or in combination with immunosuppressive therapy.

Viable tumor cells are widely used by scientists for in vitro studies about the genetic origins, molecular pathways of diseases such as cancer.

Fact.MR, Dubai: The global blood collection tubes for liquid biopsy market is exhibiting a steady growth owing to advanced healthcare facilities and favorable medical reimbursement policies.

Fact.MR, Dubai: The global nizatidine market is expected to record a steady growth due to the rising prevalence of gastrointestinal diseases such as celiac diseases, indigestion, and acid reflux.

InnoCare Pharma, a leading biopharmaceutical company, announced that the U.S. Food and Drug Administration has granted Breakthrough Therapy Designation to its Bruton’s tyrosine kinase inhibitor orelabrutinib for the treatment of relapsed or refractory mantle cell lymphoma.

Genuity Science, a genomics data, analytics and insights organization, announced its participation with leading life science technology company, 10x Genomics through 10x Genomics’ Certified Service Provider program.